Restricted to oncology physician usage in the outpatient setting for the FDA approved indications. For required hospitalizations associated with step-up dosing, doses will be administered in outpatient bed in an inpatient monitoring area. Insurance/reimbursement evaluation to be done prior to starting this drug therapy. May use as patient own medication through PAP.
Restricted to oncology physician usage in the outpatient setting for the FDA approved indications. For required hospitalizations associated with step-up dosing, doses will be administered in outpatient bed in an inpatient monitoring area. Insurance/reimbursement evaluation to be done prior to starting this drug therapy. May use as patient own medication through PAP.
Reviewed: November 2025
Mosunetuzumab-axgb (LUNSUMIO) Spotlight 10.2025 Update_Final.pdf